Advertisement

Meyka AI - Contribute to AI-powered stock and crypto research platform
Meyka Stock Market API - Real-time financial data and AI insights for developers
Advertise on Meyka - Reach investors and traders across 10 global markets
Loading...

Hexima Limited

HXL.AXASX
Healthcare
Biotechnology
$0.01
$0.00(0.00%)
Australian Market opens in 3h 4m

Hexima Limited Fundamental Analysis

Hexima Limited (HXL.AX) shows weak financial fundamentals with a PE ratio of -4.25, profit margin of 0.00%, and ROE of -32.19%. The company generates N/A in annual revenue with weak year-over-year growth of 0.00%.

Key Strengths

Cash Position71.72%
PEG Ratio-0.09
Current Ratio38.26

Areas of Concern

ROE-32.19%
Operating Margin0.00%
We analyze HXL.AX's fundamental strength across five key dimensions.

The stock receives a Fundamental Health Score of -2.2/100 based on profitability, valuation, growth, and balance sheet metrics. The F grade reflects weak fundamentals and significant financial concerns.

Fundamental Health Score

F
-2.2/100

We analyze HXL.AX's fundamental strength across five key dimensions:

Efficiency Score

Weak

HXL.AX struggles to generate sufficient returns from assets.

ROA > 10%
-32.35%

Valuation Score

Excellent

HXL.AX trades at attractive valuation levels.

PE < 25
-4.25
PEG Ratio < 2
-0.09

Growth Score

Moderate

HXL.AX shows steady but slowing expansion.

Revenue Growth > 5%
0.00%
EPS Growth > 10%
46.43%

Financial Health Score

Excellent

HXL.AX maintains a strong and stable balance sheet.

Debt/Equity < 1
0.00
Current Ratio > 1
38.26

Profitability Score

Weak

HXL.AX struggles to sustain strong margins.

ROE > 15%
-3218.99%
Net Margin ≥ 15%
0.00%
Positive Free Cash Flow
No

Key Financial Metrics

Is HXL.AX Expensive or Cheap?

P/E Ratio

HXL.AX trades at -4.25 times earnings. This suggests potential undervaluation.

-4.25

PEG Ratio

When adjusting for growth, HXL.AX's PEG of -0.09 indicates potential undervaluation.

-0.09

Price to Book

The market values Hexima Limited at 1.41 times its book value. This may indicate undervaluation.

1.41

EV/EBITDA

Enterprise value stands at 0.00 times EBITDA. This is generally considered low.

0.00

How Well Does HXL.AX Make Money?

Net Profit Margin

For every $100 in sales, Hexima Limited keeps $0.00 as profit after all expenses.

0.00%

Operating Margin

Core operations generate 0.00 in profit for every $100 in revenue, before interest and taxes.

0.00%

ROE

Management delivers $-32.19 in profit for every $100 of shareholder equity.

-32.19%

ROA

Hexima Limited generates $-32.35 in profit for every $100 in assets, demonstrating efficient asset deployment.

-32.35%

Following the Money - Real Cash Generation

FCF Per Share

Each share generates $-0.00 in free cash annually.

$-0.00

FCF Yield

HXL.AX converts -29.34% of its market value into free cash.

-29.34%

Financial Ratios Analysis

Valuation Ratios

P/E Ratio

Price to earnings ratio

-4.25

vs 25 benchmark

PEG Ratio

Price/earnings to growth ratio

-0.09

vs 25 benchmark

P/B Ratio

Price to book value ratio

1.41

vs 25 benchmark

P/S Ratio

Price to sales ratio

0.00

vs 25 benchmark

Financial Health

Debt/Equity

Total debt to shareholders' equity

0.00

vs 25 benchmark

Current Ratio

Current assets to current liabilities

38.26

vs 25 benchmark

Efficiency Ratios

ROE

Return on equity percentage

-0.32

vs 25 benchmark

ROA

Return on assets percentage

-0.32

vs 25 benchmark

ROCE

Return on capital employed

-0.19

vs 25 benchmark

How HXL.AX Stacks Against Its Sector Peers

MetricHXL.AX ValueSector AveragePerformance
P/E Ratio-4.2528.25 Better (Cheaper)
ROE-32.19%780.00% Weak
Net Margin0.00%-20122.00% (disorted) Weak
Debt/Equity0.000.30 Strong (Low Leverage)
Current Ratio38.264.66 Strong Liquidity
ROA-32.35%-14687.00% (disorted) Weak

HXL.AX outperforms its industry in 3 out of 6 key metrics, but lagging in ROE.

Historical Growth Performance

5-Year Growth Trajectory

This section reviews Hexima Limited's 5-year compound annual growth rate (CAGR) and compares its performance against the typical investment style of its industry.

Revenue CAGR

-100.00%

Industry Style: Defensive, Growth, Innovation

Declining

EPS CAGR

94.58%

Industry Style: Defensive, Growth, Innovation

High Growth

FCF CAGR

88.16%

Industry Style: Defensive, Growth, Innovation

High Growth

Fundamental Analysis FAQ